Software Improves Monitoring of Pharmaceutical Ingredients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Software Improves Monitoring of Pharmaceutical Ingredients


Pharmaceutical Technology
Volume 37, Issue 10, pp. 18
Untitled Document

Dissolution Workstation Software provides updated data integration, method change control, and instrument monitoring for controlling multiple dissolution systems. The software supports laboratory capabilities to build, edit, search, retrieve, execute, and archive all dissolution methods and test reports from a single interface. The software consolidates and maintains electronic data in one location, with options for exporting information into a laboratory information management system or into business tools such as SAP Crystal Reports or Microsoft Excel. Dissolution Workstation Software organizes, executes, and manages methods and information for all Agilent dissolution equipment, including the Agilent 708-DS, 709-DS, BIO-DIS, Apparatus 7, and dissolution sampling systems.

Agilent Technologies

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here